Featured Research

from universities, journals, and other organizations

Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests

Date:
May 29, 2000
Source:
Vanderbilt University Medical Center
Summary:
An enzyme implicated in colon cancer may also play a role in other cancers by promoting development of blood vessels to feed tumors, a Vanderbilt-Ingram Cancer Center scientist and his colleagues report.

NASHVILLE, Tenn. - An enzyme implicated in colon cancer may also play a role in other cancers by promoting development of blood vessels to feed tumors, a Vanderbilt-Ingram Cancer Center scientist and his colleagues report.

Related Articles


Writing in the June 1 issue of the Journal of Clinical Investigation, the researchers report that lung tumors in animal models grew at a slower pace when the gene for this enzyme (cyclooxygenase-2 or COX-2) was deliberately eliminated. In addition, tumor growth was significantly reduced by treatment with a drug to block COX-2 in animals that had the active COX-2 gene.

Upon closer examination, they found that, in the absence of COX-2, the tumors developed about 30 percent fewer blood vessels than those in the animals whose COX-2 gene was present and active. They also found that COX-2 levels were directly associated with levels of a growth factor that promotes the development of new blood vessels, a process called angiogenesis. In the cells missing the COX-2 gene, VEGF levels were substantially lower; with an active COX-2 gene, VEGF levels dropped after treatment with COX-2 inhibitors.

"It appears that the inhibition of tumor growth is due to lack of tumor-associated angiogenesis," said Raymond DuBois, MD, PhD, Mina Cobb Wallace Professor and Associate Director of Cancer Prevention at Vanderbilt-Ingram. "We are now examining exactly how that is controlled."

The link that is beginning to be established between COX-2 and angiogenesis - by these scientists and others - is important because it suggests selective COX-2 inhibitors might be useful as potential treatments for already established tumors.

Initially developed for arthritis, these drugs are similar to aspirin and non-steroidal anti-inflammatory drugs like ibuprofen. Aspirin and NSAIDs target both forms of the enzyme cyclooxygenase (1 and 2), both of which lead to the production of bio-active lipid hormones such as prostaglandins. Newer drugs, including the widely prescribed and marketed drug Celebrex, target only COX-2. This selectivity results in relief from pain and inflammation promoted by COX-2's prostaglandin products but leaves intact the stomach protection provided by COX-1's products.

Strong evidence over more than a decade has associated longterm use of aspirin and/or NSAIDs with a reduced risk for colon cancer. DuBois and his colleagues made the important link several years ago between elevated levels of COX-2 and the development of colon tumors. Now, DuBois is a national co-investigator in a multi-center study to test the ability of COX-2 inhibitors to prevent precancerous polyps in the colon.

In recent years, cancer researchers have turned to the field of angiogenesis as a hopeful avenue to fight cancer by more indirect means than traditional chemo- or radiation therapy. Tumors produce growth factors, such as VEGF, to recruit new blood vessels to bring the oxygen and nutrients the tumors need to grow. These vessels also provide a route for metastasis (spread of cancer cells to other parts of the body).

A number of drugs that interfere with that process are being studied in the laboratory setting as well as in patients. These drugs include an antibody that directly inhibits the action of VEGF. Scientists are also working to better understand angiogenesis in order to develop more effective means of cutting off tumor supply lines.

DuBois' colleagues in the research reported in JCI were Christopher Williams, also of the Vanderbilt-Ingram Cancer Center; Masahiko Tsujii of Osaka School of Medicine; and Jeff Reese and Sudhansu Dey of the University of Kansas Medical Center.

The work was supported by the T.J. Martell Foundation, which funds the Frances Williams Preston Laboratories at Vanderbilt-Ingram, an National Cancer Institute-designated cancer center.


Story Source:

The above story is based on materials provided by Vanderbilt University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Vanderbilt University Medical Center. "Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests." ScienceDaily. ScienceDaily, 29 May 2000. <www.sciencedaily.com/releases/2000/05/000526071547.htm>.
Vanderbilt University Medical Center. (2000, May 29). Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2000/05/000526071547.htm
Vanderbilt University Medical Center. "Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2000/05/000526071547.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins